Key terms
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AGIO news
Mar 14
12:50pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Mar 14
11:41am ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 26
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 18
11:46pm ET
Optimistic Outlook for Agios Pharma: A Buy Rating Amidst Pyrukynd Sales Miss and Promising ENERGIZE-T Trial Prospects
Feb 16
5:08am ET
Buy Rating for Agios Pharma Amid Expanding Drug Pipeline and Strong Commercial Prospects
Feb 15
4:05pm ET
Buy Rating Justified by Agios Pharma’s Promising Trials and Future Prospects
Feb 15
7:03am ET
Agios Pharmaceuticals reports 2023 EPS ($6.33), consensus ($6.26)
Feb 08
7:21am ET
Agios Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Jan 23
7:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Gilead Sciences (GILD) and Agios Pharma (AGIO)
Jan 23
7:00am ET
Agios Pharmaceuticals price target raised to $31 from $30 at JPMorgan
Jan 08
7:35am ET
Agios Pharmaceuticals announces anticipated 2024 milestones
Jan 05
8:46pm ET
Agios Pharma (AGIO) Receives a Buy from RBC Capital
Jan 05
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Jan 05
12:00am ET
Analysts Offer Insights on Healthcare Companies: Cigna (CI), Agios Pharma (AGIO) and Regeneron (REGN)
Jan 04
4:45am ET
Buy Rating Reiterated for Agios Pharma on Strong Growth Potential and Market Expansion Opportunities
Jan 03
11:06am ET
Goldman Sachs Reaffirms Their Buy Rating on Agios Pharma (AGIO)
Jan 03
6:31am ET
Agios Pharmaceuticals: Phase 3 ENERGIZE study met primary endpoint
No recent news articles are available for AGIO
No recent press releases are available for AGIO
AGIO Financials
Key terms
Ad Feedback
AGIO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AGIO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range